Close menu
August 19, 2021 Big Pharma COVID Views


Big Pharma Eyes Next Childhood Vaccine Cash Cow — mRNA Vaccines for RSV

Now that COVID vaccines have established mRNA technology as the “new frontier for vaccine development,” pharma giants have set their sights on an mRNA vaccine for respiratory syncytial virus (RSV) — which they hope to add to an already overburdened childhood vaccine schedule.

EDITOR’S NOTE: This is the first in a series of articles by The Defender on respiratory syncytial virus, commonly known as RSV. Read part two — “From Chimpanzees to Children: The Origins of RSV — Respiratory Syncytial Virus.” 

Over the decades since childhood vaccines began rolling out on a widespread scale, pediatric vaccine injuries have left many parents regretful for forgetting or ignoring a basic history lesson.

That lesson, in the words of Harvard medical historian David Jones, is that “when it comes to vaccines and immunization … there always has been a risk and there always will be a risk.”

Sixty-five years ago, families learned about the risks of medical experimentation the hard way when they allowed researchers to use their infants as test subjects for a vaccine against a newly discovered illness dubbed “respiratory syncytial virus” (RSV), a common-cold-like illness now considered to affect “virtually all children,” mostly uneventfully, by age two.

The disastrous RSV vaccine led to the death of two infants and to hospitalization for the majority of other young clinical trial participants.

Since that time, vexed researchers have continued to deploy “trial-and-error approaches.” But they admit the “road to an effective RSV vaccine is paved with challenges,” in large part because of the tricky problem of “vaccine-associated disease exacerbation” — a problem that has also plagued coronavirus vaccines.

The gist of the “exacerbation” issue, also called antibody-dependent enhancement or pathogenic priming, is that the vaccine “primes” recipients to later develop more severe disease instead of protecting them.

Lured by the prospect of a large untapped global RSV vaccine market, manufacturers are nonetheless setting their sights on RSV vaccine development — and not just for infants but also for pregnant women and the elderly.

By 2019, capitalizing on the proliferation of new vaccine technologies, clinical trials were evaluating an estimated 30 candidate RSV vaccines, and scientists were gleefully announcing that the world “might be on the brink of clinical implementation soon.”

The crowded field of RSV vaccine candidates includes messenger RNA (mRNA) vaccines. In fact, with COVID injections having opened the floodgates to establish mRNA technology as the “new frontier for vaccine development,” pharma giants appear more confident than ever that they are close to finally producing an RSV winner.

In a nod to these hopes, the U.S. Food and Drug Administration (FDA) has just granted fast-track designation to Moderna for the company’s experimental mRNA-1345 vaccine against RSV. Although the fast-track FDA review applies only to older adults for now, Moderna’s phase 1 trials of its RSV injection also include children as young as 1 year old.

What about safety?

The 1960s RSV vaccine was a disaster in terms of safety, but researchers engaged in subsequent RSV vaccine attempts have tried to steer public attention away from risks and toward a single-minded focus on effectiveness.

With the help of industry-standard study design tricks — such as monitoring adverse events for only a short while or comparing the vaccine against immune-activating aluminum adjuvants or other vaccines (rather than an inert placebo) — manufacturers have managed to keep potential safety problems in the shadows.

The foundational ethical standards underpinning research on human subjects demand special attention to vulnerable populations, including fetuses, neonates, pregnant women and the institutionalized elderly.

Yet these are precisely the populations that RSV studies have targeted — all flops, with none leading to a licensed vaccine and a bare minimum of disclosure about safety.

For example:

  • With no comparison group, Lederle Laboratories (later acquired by Wyeth Pharmaceuticals, then Pfizer, and now known as New York Center for Innovation) tested a recombinant (genetically engineered) subunit vaccine on three dozen chronically ill institutionalized persons (mean age=87) in the mid-1990s, half of whom, at baseline, “required assistance with walking or used a wheelchair.” Five died within five months of injection, but investigators reported “All deaths were due to medical conditions unrelated to the study.”
  • Wyeth administered an aluminum-adjuvanted subunit RSV vaccine or an aluminum phosphate adjuvant “control” to several hundred children ages 1-12 years with cystic fibrosis (late 1990s). Cystic fibrosis is a condition characterized by immune system defects, and aluminum adjuvants can make the immune system go haywire.
  • In the early 2000s, in a study sponsored by the National Institutes of Health, Wyeth gave three dozen healthy women in their third trimester of pregnancy its aluminum-adjuvanted subunit RSV vaccine or a saline placebo, operating under the premise (contradicted by considerable evidence) that pregnant women “respond well to vaccines.” The manufacturer monitored local and systemic reactions in the mothers for just seven days. The researchers reported no noteworthy differences in outcomes for the two groups of infants during their first year of life, although two of the vaccinated babies developed RSV anyway.
  • Between 2015 and 2018, Novavax gave more than 4600 healthy pregnant women (28-36 weeks gestation) a “fusion protein nanoparticle vaccine” or a buffer formulation (used to stabilize proteins and generally understudied for toxicity). Fifty-seven (1.2%) of the 18- to 40-year-old participants, more than half recruited in South Africa, did not progress to a live birth. Four in 10 women in the vaccine group, versus one in 10 in the placebo group, reported injection site reactions.
  • In June 2020, Pfizer launched a phase 3 trial to vaccinate pregnant women with a subunit RSV vaccine (placebo unspecified). The study design involves monitoring serious adverse events in infants for 24 months, but for only six months in mothers. The trial is ongoing.

One of the RSV vaccines entering clinical trials in recent years — including planned phase 3 trials with a “target population” of two-month-olds — is a viral vector vaccine manufactured by GlaxoSmithKline (GSK) that, like the AstraZeneca COVID shot, uses a chimpanzee adenovirus as the vector.

Interestingly, the researchers who identified RSV in the mid-1950s initially found it in chimps, not humans, and called it “chimpanzee coryza agent.” [Note: RSV’s origins will be discussed further in an upcoming article in The Defender].

The gold rush is on

Globally, the highest burden of RSV-attributed illness is in low- and middle-income countries, where 99% of fatalities occur.

For the majority of American babies for whom RSV plays out as a short-lived cough or runny nose — just like any other winter sniffles — an RSV vaccine will offer no benefit. Nor are vaccines likely to help the subset of infants who do go on to develop more serious lung inflammation (bronchiolitis) or pneumonia, children who tend to have comorbidities or weaknesses stemming from prematurity, congenital problems, neuromuscular disorders or a compromised immune system.

Yet, as the calamitous COVID injections are illustrating, virus fears — helped along by propaganda and manipulation of social psychological concepts such as social influence — can persuade parents to adopt and promote measures that run counter to their children’s interests.

To ensure ongoing panic, the media and hospitals are now reporting a summer outbreak of RSV-plus-COVID. Ironically, experts explain the “unusually high” number of RSV cases as “the result of children being largely quarantined last fall and winter, hindering them from building up an immunity.”

Unfortunately, accounts of this “wicked one-two punch” are bound to send some parents into the waiting arms of manufacturers dangling salvation in the form of an RSV vaccine, even if the injection, such as Moderna’s likely forthcoming mRNA shot, uses a technology that mRNA’s creator is warning is risky.

GSK candidly admits in materials shared with the World Health Organization that the company’s vision for its two-dose infant RSV shot is for “co-administration with routine paediatric vaccines” — in other words, incorporation into already overburdened childhood vaccine schedules.

In the U.S., the vaccine schedule for children and adolescents currently includes as many as six dozen doses through age 18: up to 27 doses of 10 vaccines (14 antigens) through 15 months of age, another 13 doses of 8 vaccines (11 antigens) through age 18, plus one to two annual flu shot doses.

The U.S. also just launched its first six-in-one shot for infants despite worrisome safety signals in Europe.

Shocked by the scale and severity of COVID vaccine injuries in their adolescents, some parents are pushing back against the “one in a million” narrative, reminding the world that there is no accountability or liability for injuries caused by any experimental or licensed vaccine.

With roughly 400 adverse events documented in the package inserts of existing childhood vaccines, other parents might do well to consider whether the risks of either RSV or COVID injections are worth the tenuous benefits.

Suggest A Correction

Share Options

Close menu

Republish Article

Please use the HTML above to republish this article. It is pre-formatted to follow our republication guidelines. Among other things, these require that the article not be edited; that the author’s byline is included; and that The Defender is clearly credited as the original source.

Please visit our full guidelines for more information. By republishing this article, you agree to these terms.